Navigation Links
NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
Date:11/1/2007

ications, including hypoparathyroidism and osteoporosis. NPS is committed to advancing the development of PREOS in hypoparathyroidism where worldwide annual sales could exceed $200 million. NPS is currently reviewing its development and commercialization options for PREOS in osteoporosis and expects to make a decision regarding this indication in the first quarter of 2008.

Third Quarter 2007 Financial Results

NPS reported net income for the third quarter of 2007 of $14.1 million, or $0.28 per diluted share, versus a net loss in the third quarter of 2006 of $21.1 million, or $0.45 per diluted share. The third quarter profit in 2007, versus a loss in the same period of 2006, reflects aggressive expense reduction measures, increased revenues from royalties and product sales, and gains from the sale of fixed assets related to site closures in Salt Lake City and Toronto.

Revenues for the third quarter of 2007 grew 190% to $29.2 million from revenues of $10.1 million in the third quarter of 2006. Increased revenues are primarily the result of higher royalty revenue earned from Amgen on sales of cinacalcet HCl and increased product sales, royalty and milestone revenue earned from Nycomed on sales of Preotact(R).

Research and development expenses for the third quarter of 2007 declined 61% to $5.4 million compared to $13.7 million for the same period of 2006. These changes are primarily due to decreased clinical development activity for PREOS, reductions in personnel, and associated cash and stock compensation, and lower pre-approval manufacturing expenses associated with PREOS, offset by higher pre-approval manufacturing expenses associated with GATTEX.

Selling, general and administrative expenses for the third quarter 2007 declined 23% to $5.7 million compared to $7.5 million for the same period in 2006. These decreases are primarily due to reductions in personnel and associated cash and stock compensation.

Restructuring charges for the
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  Replikins Ltd. today released new data on changes ... the current outbreaks, the mean Ebola Reston gene Replikin ... 1995 and 2002 was 1.1; the mean Replikin Count ... in 2013, thus predicting the current outbreaks in humans. ... shown to be able to predict outbreaks (1).  For ...
(Date:7/30/2014)... 2014 With the accelerated aging ... health expenditure as well as the improved medical ... diagnostic reagent industry has been developing quickly, especially ... 2013, Chinese in vitro diagnostics market size reached ... in vitro diagnostic reagents. , Read complete ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
(Date:7/30/2014)... MARLBOROUGH, Mass. , July 30, 2014 ... RXII ), a biotechnology company focused on ... major unmet medical needs using RNA-targeted technologies, ... study (RXI-109-1402) with RXI-109, for the reduction ... scar revision surgery, has been initiated. ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... technology professionals often face the challenge of delivering ... maximize both storage and bandwidth efficiency, while providing ... announced SecureZip, a new family of products designed ... in a cross-platform environment. The company also introduced ...
... Sanyo have announced they will work together to produce ... ,Sanyo will be working with Rayovac's I-C3 technology, which the ... in 15 minutes. I-C3, or In-Cell Charge Control, is a ... regulates the charging mechanism, rather than allowing the charger free ...
... when entrepreneur Ken Schlager started a company, he looked ... This time around, Schlager is turning to the Center ... he launches a cutting-edge technology that applies electromagnetic fields ... has developed a process that oxidizes wastewater and removes ...
Cached Biology Technology:PKWare launches new enterprise product line, adds new features to PKZip 2PKWare launches new enterprise product line, adds new features to PKZip 3CTT - Bridging the states entrepreneurial gap 2CTT - Bridging the states entrepreneurial gap 3
(Date:7/30/2014)... Americans make better decisions about what they eat, the ... significant changes to the Nutrition Facts label found on ... in Chemical & Engineering News (C&EN), the ... the suggested updates and the fight that has ... points out that while the Nutrition Facts label has ...
(Date:7/30/2014)... awarded the Scientific Committee on Antarctic Research,s (SCAR) ... SCAR, an inter-disciplinary international science body, initiates, develops ... the Antarctic region, and on the role of ... organisation also provides scientific advice about Antarctica to ... region. , The medal is open internationally to ...
(Date:7/30/2014)... a multitude of cells types. Researchers would like to understand ... mature cells that make up the organs and other structures ... long chains of sugars that dangle from proteins on surfaces ... California, San Diego, has created synthetic molecules that can stand ... manipulated to direct the process, they report in the ...
Breaking Biology News(10 mins):
... is a well-known cause of cardiovascular disease, research from the ... revealed that the body,s obesity hormones adiponectin - are ... Our skeleton is more than just bones, vertebrae ... is constantly linked to our brain, our muscles and our ...
... LANSING, Mich. Discovering new treatments and battling dangerous ... researchers targeting the genetic disorder cystic fibrosis with projects ... research studies, with support from a $110,000 grant from ... and Translational Sciences Institute, expand the relationship between the ...
... 1st, 2011) Policy decisions and poor management have ... national security, according to an article available today in ... Scientists, published by SAGE. The article calls into question ... scientists for the decline. , According to George Mason ...
Cached Biology News:4 projects target cystic fibrosis with Hunt for a Cure funds 2Structure, not scientists to blame for Los Alamos failings 2Structure, not scientists to blame for Los Alamos failings 3
... Development kit contains the basic components required ... measure natural and recombinant rat L-Selectin in ... kit contains sufficient materials to run ELISAs ... the following conditions are met: ...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
Recombinant Ovine (Sheep) Growth Hormone, Ultra Pure...
Request Info...
Biology Products: